EHA Unplugged

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while  managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities.Guests:  Dr Paula Rodríguez-Otero Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain  Host: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes.Guests:  Dr Scott Armstrong Dana-Farber Cancer Institute Prof Marc Raaijmakers Erasmus Medical CenterHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more. Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations. Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library Guest:  Prof Kai Hübel Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, GermanyHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.  Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey. Guest: Associate Prof Meritxell Alberich JordàInstitute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic Host: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠Provide Feedback⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠ 

Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (⁠Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).⁠ Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond. Guests: Prof Catherine Thieblemont and Prof Marie José Kersten.  Professor Catherine Thieblemont from Saint-Louis Hospital in Paris. Professor Marie José Kersten from Amsterdam University Medical Centers (UMC) Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠ 

In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter KapiteinHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠ Guest: Peter KapiteinHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠ 

Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy.GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in ItalyHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠Provide Feedback⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠ 

Join EHA President  Prof  Konstanze Döhner  from  University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.  Listen as  Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator.  Tune in to hear  Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those.  Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany  Host: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠Provide Feedback⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠https://ehaedu.org/Campus⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠Facebook: ⁠⁠https://e-h-a.link/facebook⁠⁠LinkedIn: ⁠⁠https://www.linkedin.com/company/eha/⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠https://eha.news/subscribe⁠⁠ 

In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis.Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process.Guest: Dr Michael MilsomHead of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, GermanyHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).  In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including  the expanding role of  BTK inhibitors (such as ibrutinib) in first-line regimens. He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy  have largely supplanted but not fully replaced allogeneic transplantation. Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges.   Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) Link to Lund University:  Mats Jerkeman - Lund University Home | Lund University  Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.What did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.  Host: Dr Sarah de VliegerGuest: Jonathan ClarkThis episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.What did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.   Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.  The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." Host: Dr Wilson LimGuest: Dr Gregor HormannLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

[This is a Rerelease. Episode first published on November 1, 2024.]Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.   Host: Dr Sarah de VliegerGuest: Dr Stephen HibbsLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

[This is a Rerelease. Episode first published on April 11, 2025.]Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: ⁠https://www.nature.com/articles/s41746-024-01076-x⁠ Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Jan Moritz MiddekeLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

Join us for this interview with Dr Río-Machín from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant. Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches. Tune in to hear dr. Río-Machín‘s call for more collaborative research to achieve impactful results for patients in the future.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Ana Río-MachínLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease. Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommendations for hematologists to ensure earlier detection of this disease. Host: Prof. Sam Salek, University of Hertfordshire, UKGuest: Prof. Argiris Symeonidis, University of Patras, Rion, GreeceLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and Mairéad Ní Chonghaile from St. James’s Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP). Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology education to nurses and other healthcare professionals to ensure the best possible care for their patients. Tune in to hear what their thoughts are on the future of nursing in hematology and how they envisage addressing its biggest challenges. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guests: Erik Aerts, Nurse Manager, University Hospital Zurich, Switzerland and President of Hematology Nurses & Healthcare Professionals Group (HNHCP) Mairéad Ní Chonghaile, Bone Marrow Transplant Coordinator, St. James’s Hospital, Dublin, Ireland and Vice-President of HNHCP Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring interview with prof. Jesús San-Miguel from Clínica Universidad de Navarra in Spain who discusses his extensive work to improve care for patients with multiple myeloma. Prof San-Miguel’s research and clinical contributions have shaped the current treatment landscape for multiple myeloma. For his contributions, he has received the 2025 EHA Lifetime Achievement Award. Tune in to hear his thoughts about the future of multiple myeloma management and the crucial role that collaborative research will play in it.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Jesús San-Miguel, Clínica Universidad de Navarra, SpainLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this interview with Dr Mandy Lauw from Erasmus Medical Center in Rotterdam, Netherlands who describes her work to increase the visibility and voice of young hematologists within the EHA. For her unwavering efforts to improve the support and opportunities for young hematologists at the beginning of their career, Dr Lauw has been awarded the Young EHA Award. Tune in to hear about the many educational and mentoring programs EHA has available for young hematologists. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Mandy LauwLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this interview with Dr Ferran Nadeu Prat from August Pi i Sunyer Biomedical Research Institute in Barcelona, Spain who discusses his work on evolution of chronic lymphocytic leukemia (CLL), which he conducted thanks to the EHA Junior Research Grant. Dr Nadeu Prat explains how the new insights into CLL evolution toward Richter transformation, which is a lethal complication of CLL, may lead to new therapeutic approaches. Tune in to hear his views on the future of this field and the role of collaborative research in achieving these goals.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Ferran Nadeu Prat, August Pi i Sunyer Biomedical Research Institute, Barcelona, SpainLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this conversation with prof. Mariane de Montalembert from Necker-Enfants Malades Hospital in France who discusses the current standards of care for patients with sickle cell disease and thalassemia, both in Europe and in sub-Saharan Africa. Prof. de Montalembert highlights the inequalities and the unique challenges in implementation of complex innovative treatments, such as gene therapy. Tune in to hear her thoughts on the possible solutions for these challenges and future directions in this field. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Mariane de Montalembert, Necker-Enfants Malades Hospital, Paris, FranceLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring interview with prof Béatrice Gulbis from The Brussels University Hospital in Belgium who discusses her extensive work on implementing neonatal screening for sickle cell disease (SCD) in low-resource countries in Africa. Prof Gulbis has been involved in collaborative projects to implement the testing methods that best fit the specific contexts. Tune in to hear her recommendations for the optimal SCD screening systems and her hopes for the worldwide collaborative approach to improve care for patients with SCD.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Béatrice Gulbis, The Brussels University Hospital, BelgiumLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this interview with dr. Côme Bommier from Saint-Louis Hospital in Paris, France who describes the results of the recent EHA survey on burnout symptoms among hematology professionals in Europe. Dr. Bommier discusses the findings of the survey in the context of modifiable systemic factors. Tune in to hear him urge organizational reforms to ensure better work environments for hematologists, leading ultimately to better outcomes for patients. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Côme Bommier, Saint-Louis Hospital, Paris, FranceLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring conversation with prof. Anna Schuh from University of Oxford in the United Kingdom who describes her efforts to improve access to care for patients with hematological diseases in East African countries. Prof. Schuh describes the experience of sharing her time between the UK and East Africa and how this has impacted her clinical practice in both environments. Tune in to hear what her views are on how the Global North and Global South can learn from each other to improve care for patients everywhere. Host: Wilson Lim, PhD, Medical Writer Guest: Prof Anna Schuh, University of Oxford, United KingdomLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspirational interview with prof. Jan Cools from KU Leuven in Belgium who received the EHA 2025 Education & Mentoring Award. Prof. Cools describes his approach to mentoring students and scientists, emphasizing the aspects that he finds most crucial in this role. Tune in to hear his thoughts about the future of mentoring, the place artificial intelligence may take in it and the importance of failure on the road to success.Host: Isabel Olivera-Martinez, PhD, Medical Writer, EHA Guest: Prof. Jan Cools, KU Leuven Department of Human Genetics, BelgiumLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, we sit down with prof. Khaled Musallam from Burjeel Medical City in United Arab Emirates who discusses his extensive work to improve care for patients with thalassemia. Prof. Musallam’s research and clinical contributions have reshaped the management of both non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT). Tune in to hear his views on the current practice and future directions in the prevention and treatment of morbidities associated with thalassemia. For a comprehensive review of all aspects of thalassemia, the EHA Thalassemia Program is available to all EHA Members on Campus. Stay tuned for future episodes!Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Khaled MusallamLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this discussion between Robin Doeswijk, EHA European Affairs and prof. John Gribben from Barts Cancer Institute in the United Kingdom on the topic of equity in care of patients with hematologic malignancies. This discussion follows the recently published “European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological Malignancies”. Tune in to hear how this combination of organizational guidelines and clinical practice recommendations aims to improve diagnosis and care for all patients across Europe.Host: Robin Doeswijk, EHA European AffairsGuest: Prof John GribbenLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this captivating interview with Prof Kirsten Grønbæk from University of Copenhagen in Denmark, as she discusses her outstanding career in the field of hematology, both in research and in the clinics. Listen to how the interests of Prof Grønbæk evolved, leading her from the initial focus on epigenetics in lymphomas to MDS in the later years of her career. Prof Grønbæk reflects on the current developments in MDS and her tips for the leading a successful research team in hematology. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Kirsten GrønbækLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, we sit down with Prof. Maria Domenica Cappellini from the University of Milan in Italy, as she discusses her inspiring career as a hematologist specializing in the management of patients with thalassemia. Listen to the compelling story of how Prof. Cappellini’s interest in thalassemia started and how her relentless stride for the best possible care for her patients has helped to transform the way this disease is managed. Tune in to hear prof. Cappellini’s words of advice for the younger generation of hematologists interested in the field of thalassemia.  Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Maria Domenica CappelliniLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Explore the latest breakthroughs in gene therapy for sickle cell disease and beta thalassemia with Dr. Stefano Rivella, hematologist and research faculty at Children's Hospital of Philadelphia.  In this episode, Dr. Rivella discusses the science behind FDA-approved therapies, compares gene addition and gene editing approaches, and shares insights on clinical safety, efficacy, and future innovations like in vivo gene therapy.  Learn about the challenges of access, cost, and global equity, and discover how evolving technologies could transform treatment for patients worldwide. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Stefano RivellaLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this insightful interview with prof. Hartmut Döhner from University Hospital Ulm in Germany who tells about most recent developments in the management of older and unfit patients with AML. Prof. Döhner discusses all key aspects of the management including assessing patient fitness, genetic risk classification, and the choice of treatment, among which also the emerging therapies. Tune in, to hear about the most relevant recommendations for the clinical decision making while treating older unfit patients with AML.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Hartmut Döhner, University Hospital Ulm, GermanyLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also shares her thoughts on the future of the treatment landscape for AML.  Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Konstanze DöhnerLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Listen as Prof. Christian Chabannon from Aix Marseille Université in France who tells about GoCART Coalition in this new podcast episode. The main goal of this coalition, which unites expertise from many fields, is to promote access to novel cellular therapies, such as CAR T-cells. Prof. Chabannon explain how GoCART is working on reaching this goal by generating new clinical insights, improving standards of care, providing education and building policy. Tune in to learn more about the impact of this coalition on healthcare today and in the future.      Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof. Christian ChabannonLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Jan Geissler from Germany tells about his work as a patient advocate in the field of hematological malignancies. As a cancer survivor, patient advocate and patient engagement expert, Jan has been working tirelessly for many years in organizations such as European Patients Academy (EUPATI), Patvocates and many others. Listen to Jan’s passionate call for a collaborative spirit to achieve the best outcomes for patients. Tune in to hear his views on patient advocacy and the impact it has on patient care.   Stay tuned for future episodes!   Guest: Jan Geissler, Patient Advocate, Germany Host: Isabel Olivera-Martinez, PhD, Medical Writer   Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Prof. Maria Themeli tells about most recent developments in the field of “off-the-shelf” CAR T-cells. As the clinical success of advanced cellular therapies is growing, so is the need for broader access to these treatments. Listen as Prof. Themeli summarize the state-of-the-art technology that aims to generate “off-the-shelf” CAR T-cells from sources such as induced pluripotent stem cells (iPSCs) and how this approach may offer a feasible strategy to improve clinical outcomes and reduce the costs of advanced cellular therapies in the future.    Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Maria ThemeliLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join dr. Carmen Sanges from University Clinic Würzburg in Germany as she tells us about AIDPATH. This collaborative initiative is dedicated to improving access to advanced cellular therapies by employing artificial intelligence (AI) in the production process. Listen to dr. Sanges explain how AI technology is used to integrate patient-specific information and biomarkers to optimize CAR-T therapy. Tune in to hear about the current approaches and future directions of this cutting-edge technology. Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, Medical Writer Guest: Dr Carmen SangesLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring interview with prof. Elizabeth Macintyre from Université Paris Cité in France who tells us about her professional journey in hematology. Listen to prof. Macintyre discuss her views on the current state and future directions of advanced diagnostics in malignant hematology and their implications for healthcare management and the training of young specialists. Tune in to hear how Biomedical Alliance may impact future policies through “trans-European” approaches. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Elizabeth MacintyreLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings.  This conversation highlights the challenges in defining "low-risk" MDS, the role of genetic mutations in prognosis, and the considerations for treatment strategies, including the potential for stem cell transplantation.   Host: Professor Kirsten Gronbaek, University of Copenhagen, Denmark Guest: Professor Uwe Platzbecker, University Clinic of LeipzigLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques used for MRD detection.   Listen as they explore the challenges and potential strategies for MRD monitoring in MDS, and the implications for treatment decisions. This episode is a must-listen for anyone interested in the latest advancements in hematology and the future of MRD monitoring in MDS.  Tune in to EHA Unplugged to gain valuable insights and stay updated with the latest research and clinical practices in hematology.Host: Prof Kirsten GronbaekGuest: Prof Arjan van de LoosdrechtLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher. Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-border teamwork in clinical trials and the importance of European cooperation highlights the impact that these initiatives had on prof. Dreyling’s career. Tune in to hear his thoughts about the future directions in lymphoma treatment and collaborative clinical research in general.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: prof. Martin DreylingLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, prof. Kirsten Gronbaek and dr. Shahram Kordasti discuss the role of immune dysfunction in MDS. With the improving understanding of complex pathophysiology of MDS, the major role of the immune system in this process is becoming increasingly apparent. Listen to dr. Kordasti discuss the multifactorial interactions between the malignant clones and the inflammatory environment, manifesting in elements of autoimmunity and elements of autoinflammation in MDS. As the complexity of immunophenotypes observed in MDS is being unraveled, the need to include immunophenotypic factors in the prognostic scores is growing. Tune in to hear dr. Kordasti’s and prof. Gronbaek’s thoughts on the future of prognostication, the more comprehensive approach for patient stratification designed to predict therapy responses and the future of immunotherapy in MDS.Host: Prof Kirsten GronbaekGuest: Dr Shahram KordastiLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this interview, dr. Maria del Mar Mañu Pereira from Vall d’Hebron Research Institute in Spain talks about the Rare Anemia Disorders European Epidemiological Platform (RADeep). RADeep is an initiative of ERN-EuroBloodNet and functions as an umbrella for both new and already existing European patients' registries in rare anemia disorders.  Listen to dr. Mañu Pereira talk about the history of RADeep from its early days until today and about its ambitious goals to advance research and promote best practices in care for RAD patients across Europe. You will hear about the milestones achieved, current research, and how RADeep registry and the ENROL (European Rare Blood Disorders Platform) initiative complement each other to achieve optimal health outcomes for RAD patients.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Maria del Mar Mañu PereiraLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Prof. Antonio Almeida from Hospital da Luz in Lisbon takes us through his professional journey in hematology as a clinician and educator, and his current role as the President of EHA. Listen to prof. Almeida recount his professional path that allowed him to experience various facets of hematological clinical practice in the UK and Portugal. Alongside his career as a hematologist, prof. Almeida cultivated a growing love for education, where he tries to employ student-centered techniques to enhance educational experiences. Tune in to hear how prof. Almeida describes his journey to becoming the President of EHA and what he sees as today’s most significant challenges in hematology and what solutions he has in mind to address those. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof. Antonio AlmeidaLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options. He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future. Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS.  Host: prof. Kirsten GronbaekGuest: prof. Dominik WolfLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: https://www.nature.com/articles/s41746-024-01076-x Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Jan Moritz MiddekeLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic process. The conversation also touches on the potential of artificial intelligence in diagnostics, the prognostic value of genetic mutations, and the importance of considering germline disorders in MDS. This episode is a must-listen for healthcare professionals seeking to deepen their understanding of MDS diagnostics. Host: Prof Kirsten GrønbækGuest: Dr Onima ChowdhuryLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator. Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development. Prof. Huntly also touches on the concepts of early interception and tumor-specific and tumor-nonspecific areas to personalized medicine. Tune in to hear how prof. Huntly combines his work in the fields of science and clinical medicine and what his recommendations are for younger colleagues, who are in the early stages of their careers. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Brian Huntly Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

In this podcast, Prof Dame Lesley Fallowfield and Prof Clemens Wendtner discuss patient mental health and communication in the context of Chronic Lymphocytic Leukemia (CLL) treatment. They explore the psychological impact of CLL and leukemia in general, the importance of patient communication, and the need for integrated mental health support. The conversation highlights the challenges of explaining complex medical concepts to patients and the role of resilience in both patients and physicians. They also address the challenges of managing patient anxiety and depression, the role of trust in the doctor-patient relationship, the importance of empathy, and the need for integrated psychological support services.Guests: Prof Dame Lesley Fallowfield Prof Clemens WendtnerNote: This podcast is based on content provided by BeiGene. It has been reviewed by EHA, which found it unbiased and aligned with EHA educational standards, as well as edited by EHA to create an effective educational experience.Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with patient advocates Miriam Santos Freire (sickle cell disease) and Loris Brunetta (beta-thalassemia major). Benefit from their experiences as they discuss with our host Isabel Olivera-Martinez the promises and challenges of gene therapy for these conditions.Listen to their experiences of living with these genetic conditions while they highlight the disparities in treatment access between wealthy and low-income countries. Both view gene therapy as a breakthrough that has the potential to cure these diseases, but express caution regarding its current limitations and complications. Tune in for their valuable insights and recommendations for advancing SCD and thalassemia management.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guests:Miriam Santos Freire, Patient representative for EuroBloodNetPatient Advocacy & Communication for Sickle Cell (Portugal & UK) at European Sickle Cell Federation (ESCF)European Hematology Association (EHA)ERN-EuroBloodNetAssociação Portuguesa de Pais de Doentes com Hemoglobinopatias (APPDH) – also a Board MemberLoris BrunettaBoard Member of Thalassaemia International Federation (TIF), Vice-chair of EHA Patients’ Advocacy Committee (PAC), Member of the Patients and Consumer Working Party (PCWP) at EMA, EMA expert on ESEC, Former member of Committee for Orphan Medicinal Products (COMP) at EMA, ePAG at EuroBloodNet, Coordinator of the Italian Associations Advocacy Council (IAAC) President of Associazione Ligure Thalassemici (Italy).Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice. Prof Stamatopoulos describes here his work into stereotypy of B-cell receptor (BCR) immunoglobulin and how this phenomenon explains the existence of the same or highly similar subsets of BCR clones in unrelated patients with CLL. Our guest explains further how this knowledge is leading to the classification of CLL patients into subsets with specific pathologies and might help personalize the treatment. Next to translational research, Prof Stamatopoulos is focusing on patient empowerment. In this podcast, he will explain how he strives to create a more participatory healthcare model, and how he aims to transform education and training for young clinicians and researchers. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Kostas StamatopoulosLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe